| 释义 |
plas·min·o·gen 英plæzˈmɪnədʒən美plæzˈmɪnədʒənAHDplăz-mĭnʹ-ə-jən 高COCA¹²¹³⁴²BNC¹⁵⁷⁸³iWeb⁴²⁴³⁴
基本英英记法例句
n.生血纤维蛋白溶酶原;血浆酶原¹⁰⁰
Noun:
an inactive form of plasmin that occurs in plasma and is converted to plasmin by organic solventsplasminogen-生成⇒n.生血纤维蛋白溶酶原;血浆酶原 Changes in cerebromicrovessel basement membrane after I/ R injury in the aged SD rats is related to change in plasminogen activator system.
在脑 I/ R微血管基底膜损伤方面，老龄大鼠较青年严重，其损伤的特点与纤溶酶原激活系变化有关。 cnki
The present study, using the different catecholamines, observed the effects on plasminogen activator PA activity release in the vascular wall of rat hind legs.
用不同浓度儿茶酚胺灌流大鼠下肢血管床，观察它们对血管内皮细胞释放纤溶酶原激活剂 PA的作用。 cnki
The results of theoretical analysis indicate that ILLLIT surely can enhance the activity of plasminogen activator, which is advantageous to decreasing the aggregate degree of erythrocyte.
理论分析表明 IL L LIT提高了纤维蛋白溶酶原激活素的活性，有利于红细胞聚集指数的下降。 cnki
The effective fraction of SQ complex prescription decreased the contents of tissue-type- plasminogen activator t- PA.
SQ复方有效部位能降低组织型纤溶酶原激活物 t- PA含量。 cnki
The high- phenol group also experienced a greater drop in the activity of another clot promoter, plasminogen activator inhibitor-1.
高酚早餐组另一血栓促进因子——纤维蛋白溶酶原活化抑制因子-1的活性也呈现显著降低。 dxy
AIM To verify the assisting effect of berberine BR of its antiplatelet rich plasma clot retraction effect on different plasminogen activator induced thrombolysis.
目的验证小檗碱 BR抗富含血小板血浆凝块收缩对两种纤溶酶原激活物引发的溶栓作用的协助。 cnki
Erythrina trypsin inhibitor ETI is a natural serine protease inhibitor, with high inhibitive activity to trypsin, chymotrypsin and tissue-type plasminogen activator t- PA.
刺桐胰蛋白酶抑制剂 ETI是一种丝氨酸蛋白酶抑制剂，可抑制胰蛋白酶、胰凝乳蛋白酶及组织纤溶酶原激活剂 t- PA等。 dictall
Intravenous administration of recombinant tissue plasminogen activator remains the most beneficial proven intervention for emergency treatment of stroke.
在卒中的介入急救中，静脉注射重组组织纤溶酶原激活剂依然被认定为最有效的。 med66
Objective To construct an expression vector for highly efficient expression of tissue-type plasminogen activator t- PA confined in the mammary gland of cow to develop a cow mammary gland bioreactor.
目的构建组织型纤溶酶原激活剂 t- PA乳腺定位表达载体，使其在牛乳汁中高效表达，从而建立牛乳腺生物反应器。 dictall
Objective To explore the relationship between plasminogen activator inhibitor type-1 PAI-1 and its biological behaviour of hepatocellular carcinoma HCC.
目的研究纤溶酶原激活物抑制剂 PAI-1与肝癌临床生物学特性的关系。 cnki
Objective To explore the relationship between the activity change of tissue type plasminogen activator TPA of retinas and retinal edema in retinal ischemia and reperfusion rats.
目的探讨缺血-再灌注对大鼠视网膜分泌组织型纤溶酶原激活物 TPA的影响及其与视网膜水肿的关系。 dictall
Objective To investigate the expression and role of urokinase-type plasminogen activatorbpa in the invasion and metastasis of NPC.
目的探讨尿激酶型纤溶酶原激活剂在鼻咽癌组织中的表达及其与鼻咽癌侵袭和转移的关系。 cnki
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor1 PAI1 by human pleural mesothelial cells HPMC.
目的研究前炎症细胞因子对人胸膜间皮细胞 HPMC释放纤溶酶原激活物抑制剂 PAI1的诱导效应。 cnki
Objective To investigate the plasma tissue-type plasminogen activator t- PA and plasminogen activator inhibitor PAI in coronary heart disease patients with angina pectoris and its probable mechanism.
目的探讨冠心病心绞痛病人血浆组织型纤溶酶原激活物 t PA及其抑制物 PAI活性的变化及其可能机制。 cnki
Objective To study the relationship of plasminogen activator inhibitor type1 PAI1 to platelet activity in elderly patients with unstable angina pectoris UAP.
目的探讨老年不稳定型心绞痛 UAP与纤溶酶原激活物抑制剂1型 PAI1及血小板活化功能的临床意义。 cnki
Objective To study the effects of transient cerebral ischemic reperfusionIR and flunarizine on the expression of plasminogen activator inhibitor-1 PAI-1 protein in brain tissue of gerbils.
目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂 PAI-1蛋白表达变化，以及西比灵干预的影响。 cnki
Objective To study the expression of plasminogen activator inhibitor-1 PAI-1 of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis AS.
目的通过对动脉粥样硬化 AS兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1 PAI-1表达的研究，探讨 PAI-1在 AS中的作用。 cnki
Objective: To identify the significance of urokinase- type plasminogen activator UPA expression in patients with epithelial ovarian carcinoma.
目的：探讨尿激酶型纤溶酶原激活因子 UPA的蛋白表达与上皮性卵巢癌生物学行为的关系。 cnki
Objective: To investigate the clinical effectiveness of prolonged low-dose urine plasminogen activator u- PA therapy in patients with unstable angina pectoris UAP.
目的：观察小剂量长疗程尿纤溶酶原激活物 u- PA治疗不稳定型心绞痛 UAP的临床疗效。 cnki
Objective:To observe the activity of fibrinolysis and plasminogen activatorPAcaused by papain in vitro.
目的：初步观察木瓜蛋白酶体外的纤溶活性及纤溶酶原激活活性。 cnki
ObjectivesTo study the change of plasminogen activation system in different behavior type patients with coronary heart disease.
目的研究不同行为类型冠心病患者之间纤溶激活系统的变化。 cnki
ObjectiveTo study the role and significance of plasminogen activator inhibitor-1 PAI-1 in renal fibrosisRF after damage and elucidate the molecular pathogenetic mechanisms of RF.
为探讨纤溶酶原激活物抑制因子1 PAI1在肾损伤后纤维化中的作用和意义，揭示其发病的分子病理机制。 cnki
Plasmin and plasminogen is a major pair of alkaline proteinase in milk, which affects dairy products by hydrolyzing milk proteins.
纤维蛋白酶及其酶原是存在于乳中的一对主要碱性蛋白酶，通过水解乳蛋白对乳及乳制品的品质产生影响。 dictall
Recently, a lot of studies have been demonstrated that SPC increased cell migration and induced the expression of plasminogen activator related to cell migration.
最近发现 SPC促进细胞的移动，诱导成纤维细胞表达与细胞移动有关的血纤维蛋白溶酶原激活剂。 cnki
Reciprocal activation of prourokinase and plasminogen is an important mechanism in the initiation and propagation of local fibrinolytic activity.
纤溶酶原和尿激酶前体的相互活化作用在纤溶的开始和加速上发挥着重要的作用。 dictall
Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。 cnki
We studied the mechanism of plasma and tissue kallikrein in activating plasminogen.
作者研究了血浆和组织激肽释放酶激活纤溶酶原的机制。 cnki
Plasminogen activator inhibitor-1 PAI-1 is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂 PAI-1是纤溶系统的主要调控因子。 chemyq
Plasminogen activators are widely used as thrombolytic drugs clinically, while they are far away from perfect and urgent requests call for development of new thrombolytic drugs.
已临床使用的溶栓药物主要是纤溶酶原激活剂类，但还存在许多缺陷，因此新型溶栓药物的研制迫在眉睫。 kns50.chkd.cnki.net |